Loading clinical trials...
Loading clinical trials...
The purpose of this extension study is to determine the long-term safety and tolerability of an investigational treatment (LUM001 also known as Maralixibat) in children with ALGS who have completed pa...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Mirum Pharmaceuticals, Inc.
NCT05035030 · Alagille Syndrome
NCT06850038 · Alagille Syndrome
NCT07293897 · Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT05543174 · Alagille Syndrome (ALGS)
NCT02963077 · Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis, and more
Birmingham Children's Hospital
Birmingham, West Midlands
Leeds Teaching Hospital NHS Trust
Leeds, West Yorkshire
Kings College Hospital
London
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions